International Journal of Antimicrobial Agents
Volume 35, Issue 6 , Pages 559-565 , June 2010

In vivo efficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infections

  • Andrew P. Desbois

      Affiliations

    • Biomedical Sciences Research Complex, School of Biology, University of St Andrews, The North Haugh, Fife KY16 9ST, UK
    • ,
  • Curtis G. Gemmell

      Affiliations

    • Bute Medical Building, School of Medicine, University of St Andrews, Fife KY16 9TS, UK
    • ,
  • Peter J. Coote

      Affiliations

    • Biomedical Sciences Research Complex, School of Biology, University of St Andrews, The North Haugh, Fife KY16 9ST, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 1334 463 406; fax: +44 1334 462 595.

Received 14 December 2009 ,Accepted 14 January 2010.

References 

  1. Gemmell CG, Edwards DI, Fraise AP, Gould FK, Ridgway GL, Warren RE. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother. 2006;57:589–608
  2. Tai CC, Nirvani AA, Holmes A, Hughes SPF. Methicillin-resistant Staphylococcus aureus in orthopaedic surgery. Int Orthop. 2004;28:32–35
  3. Gould IM. Costs of hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) and its control. Int J Antimicrob Agents. 2006;28:379–384
  4. Boyle-Vavra S, Carey RB, Daum RS. Development of vancomycin and lysostaphin resistance in a methicillin-resistant Staphylococcus aureus isolate. J Antimicrob Chemother. 2001;48:617–625
  5. Hancock REW. Peptide antibiotics. Lancet. 1997;349:418–422
  6. Ghiselli R, Giacometti A, Cirioni O, Orlando F, Mocchegiani F, Mataloni Pacci G, et al. Therapeutic efficacy of the polymyxin-like peptide ranalexin in an experimental model of endotoxemia. J Surg Res. 2001;100:183–188
  7. Andrès E, Dimarcq JL. Cationic peptides: update of clinical development. J Intern Med. 2005;255:519–520
  8. Patron RL, Climo MW, Goldstein BP, Archer GL. Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin. Antimicrob Agents Chemother. 1999;43:1754–1755
  9. Kokai-Kun JF, Chanturiya T, Mond JJ. Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model. J Antimicrob Chemother. 2007;60:1051–1059
  10. Graham S, Coote PJ. Potent, synergistic inhibition of Staphylococcus aureus upon exposure to a combination of the endopeptidase lysostaphin and the cationic peptide ranalexin. J Antimicrob Chemother. 2007;59:759–762
  11. Desbois AP, Lang S, Gemmell CG, Coote PJ. Surface disinfection properties of the combination of an antimicrobial peptide, ranalexin, with an endopeptidase, lysostaphin, against methicillin-resistant Staphylococcus aureus (MRSA). J Appl Microbiol. 2010;108:723–730
  12. Clark DP, Durell S, Maloy WL, Zasloff M. A novel antimicrobial peptide from bullfrog (Rana catesbeiana) skin, structurally related to the bacterial antibiotic, polymyxin. J Biol Chem. 1994;14:10849–10855
  13. Giacometti A, Cirioni O, Ghiselli R, Goffi L, Mocchegiani A, Riva A, et al. Efficacy of polycationic peptides in preventing vascular graft infection due to Staphylococcus epidermidis. J Antimicrob Chemother. 2000;46:751–756
  14. Giacometti A, Cirioni O, Ghiselli R, Goffi L, Mocchegiani F, Riva A, et al. Polycationic peptides as prophylactic agents against methicillin-susceptible or methicillin-resistant Staphylococcus epidermidis vascular graft infection. Antimicrob Agents Chemother. 2000;44:3306–3309
  15. Babich H, Borenfreund E. Cytotoxicity of T-2 toxin and its metabolites determined with the neutral red cell viability assay. Appl Environ Microbiol. 1991;57:2101–2103
  16. Gründling A, Missiakas DM, Schneewind O. Staphylococcus aureus mutants with increased lysostaphin resistance. J Bacteriol. 2006;188:6286–6297
  17. White RL, Burgess DS, Mandura M, Bosso JA. Comparison of three different in vitro methods of detecting synergy: time–kill, checkerboard, and E test. Antimicrob Agents Chemother. 1996;40:1914–1918
  18. Morton JJP, Malone MH. Evaluation of vulnerary activity by an open wound procedure in rats. Arch Int Pharmacodyn Ther. 1972;196:117–126
  19. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6:65–70
  20. Ciornei CD, Sigurdardóttir T, Schmindtchen A, Bodelsson M. Antimicrobial and chemoattractant activity, lipopolysaccharide neutralization, cytotoxicity, and inhibition by serum of analogs of human cathelicidin LL-37. Antimicrob Agents Chemother. 2005;49:2845–2850
  21. Fletcher J. Best practice—choosing an appropriate antibacterial dressing. Nurs Times. 2006;102:46–49
  22. Peter FW, Li-Peuser H, Vogt PM, Muehlberger T, Homann HH, Steinau HU. The effect of wound ointments on tissue microcirculation and leucocyte behaviour. Clin Exp Dermatol. 2002;27:51–55
  23. Vick LR, Propst RC, Bozeman R, Wysocki AB. Effect of Dakin's solution on components of a dermal equivalent. J Surg Res. 2009;155:54–64
  24. Cooper R. A review of the evidence for the use of topical antimicrobial agents in wound care. World Wide Wounds; 2004;http://www.worldwidewounds.com/2004/february/Cooper/Topical-Antimicrobial-Agents.html (accessed 12.11.09)
  25. White R, Cutting KF. Modern exudate management: a review of wound treatments. World Wide Wounds; 2006;http://www.worldwidewounds.com/2006/september/White/Modern-Exudate-Mgt.html (accessed 12.11.09)
  26. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis. 2001;33(Suppl. 3):S147–S156
  27. Coates A, Hu Y, Bax R, Page C. The future challenges facing the development of new antimicrobial drugs. Nat Rev Drug Discov. 2002;1:895–910
  28. Climo MW, Ehlert K, Archer GL. Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2001;45:1431–1437
  29. Giacometti A, Cirioni O, Barchiesi F, Scalise G. In vitro activity and killing effect of polycationic peptides on methicillin-resistant Staphylococcus aureus and interactions with clinically used antibiotics. Diagn Microbiol Infect Dis. 2000;38:115–118
  30. Marty FM, Yeh WW, Wennersten CB, Venkataraman L, Albano E, Alyea EP, et al. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol. 2006;44:595–597
  31. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet. 2001;358:207–208
  32. Werner G, Cuny C, Schmitz FJ, Witte W. Methicillin-resistant, quinupristin–dalfopristin-resistant Staphylococcus aureus with reduced sensitivity to glycopeptides. J Clin Microbiol. 2001;39:3586–3590
  33. Cepeda J, Hayman S, Whitehouse T, Kibbler CC, Livermore D, Singer M, et al. Teicoplanin resistance in methicillin-resistant Staphylococcus aureus in an intensive care unit. J Antimicrob Chemother. 2003;52:533–534
  34. Quickel KE, Selden R, Caldwell JR, Nora NF, Schaffner W. Efficacy and safety of topical lysostaphin treatment of persistent nasal carriage of Staphylococcus aureus. Appl Microbiol. 1971;22:446–450
  35. Harrison EF, Fuquay ME, Zygmunt WA. Antigenic response to topically applied proteins. Infect Immun. 1975;11:309–312
  36. Daley MJ, Oldham ER. Lysostaphin: immunogenicity of locally administered recombinant protein used in mastitis therapy. Vet Immunol Immunopathol. 1992;31:301–312
  37. Climo MW, Patron RL, Goldstein BP, Archer GL. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis. Antimicrob Agents Chemother. 1998;42:1355–1360
  38. Dajcs JJ, Thibodeaux BA, Girgis DO, Shaffer MD, Delvisco SM, O’Callaghan RJ. Immunity to lysostaphin and its therapeutic value for ocular MRSA infections in the rabbit. Invest Ophthalmol Vis Sci. 2002;43:3712–3716

PII: S0924-8579(10)00061-0

doi: 10.1016/j.ijantimicag.2010.01.016

International Journal of Antimicrobial Agents
Volume 35, Issue 6 , Pages 559-565 , June 2010

Article Tools

* Image Usage & Resolution